The increase in the MDM2 level could potentially counteract p53-induced apoptosis and may reduce the antitumor efficacy of the drug, which was shown as incomplete tumor cell death by CGM097 in our in vitro and in vivo studies. Here, TP53 is linked to neoplasm.